(Q34342199)

1 August 2017

title

Treatment of autoimmune liver disease: current and future therapeutic options (English)

1 reference

1 August 2017

1 reference

Gideon M. Hirschfield

object named as

Gideon M Hirschfield

series ordinal

2

0 references

author name string

Palak J Trivedi

series ordinal

1

1 reference

1 August 2017

language of work or name

1 reference

1 May 2013

1 reference

Therapeutic advances in chronic disease

1 August 2017

published in

1 reference

1 August 2017

volume

4

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

119-141

1 reference

Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Review article: overlap syndromes and autoimmune liver disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

PSC, AIH and overlap syndrome in inflammatory bowel disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Autoimmune hepatitis in special patient populations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Towards common denominators in primary biliary cirrhosis: the role of IL-12

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Pathophysiology and current management of pruritus in liver disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

The role of CXCR3 in the induction of primary biliary cirrhosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Bile acids for primary sclerosing cholangitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Disease-specific autoantibodies in primary biliary cirrhosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: Results of a 9year follow-up

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Diagnosis and management of autoimmune hepatitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Primary sclerosing cholangitis: the role of extrahepatic biliary resection

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Autoimmune liver disease for the non-specialist

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis--overlapping or separate diseases?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Ursodeoxycholic acid for primary biliary cirrhosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

The natural history of small-duct primary sclerosing cholangitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Immunology of the gut and liver: a love/hate relationship.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Hepatic and extrahepatic malignancies in primary sclerosing cholangitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Short-term cyclosporine induces a remission of autoimmune hepatitis in children.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Oral budesonide for treatment of autoimmune chronic active hepatitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

A prospective trial of colchicine for primary biliary cirrhosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Long-term follow-up of chronic active hepatitis of moderate severity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis

21 January 2018

2 references

https://api.crossref.org/works/10.1177%2F2040622313478646

21 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

27 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Rapidity of treatment response and outcome in type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Mycophenolate mofetil as second line therapy in autoimmune hepatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Transplantation trends in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Fenofibrate treatment in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Treatment response in patients with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Is bezafibrate histologically effective for primary biliary cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Long-term outcome of Japanese patients with type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3629750

FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency

27 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2040622313478646

21 January 2018

1 reference

12 December 2020

Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease

1 reference

12 December 2020

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

1 reference

12 December 2020

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial

1 reference

12 December 2020

Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience

1 reference

12 December 2020

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial

1 reference

12 December 2020

Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study

1 reference

12 December 2020

A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis

1 reference

12 December 2020

Small-duct primary sclerosing cholangitis: a long-term follow-up study

1 reference

12 December 2020

A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results

1 reference

12 December 2020

British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis

1 reference

12 December 2020

Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis

1 reference

12 December 2020

Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial

1 reference

12 December 2020

The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes

1 reference

12 December 2020

A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid

1 reference

12 December 2020

Severe chronic active liver disease. Prognostic significance of initial morphologic patterns

1 reference

12 December 2020

A prospective controlled trial of azathioprine in primary biliary cirrhosis

1 reference

12 December 2020

Azathioprine for Long-Term Maintenance of Remission in Autoimmune Hepatitis

1 reference

12 December 2020

Features and consequences of untreated type 1 autoimmune hepatitis

1 reference

12 December 2020

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

1 reference

12 December 2020

Consequences of treatment withdrawal in type 1 autoimmune hepatitis

1 reference

12 December 2020

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

12 December 2020

Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome

1 reference

12 December 2020

Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse

1 reference

12 December 2020

Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis

1 reference

12 December 2020

Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study

1 reference

12 December 2020

Early normalisation of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients

1 reference

12 December 2020

Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis

1 reference

12 December 2020

Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol

1 reference

12 December 2020

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

12 December 2020

Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses

1 reference

12 December 2020

Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis--report of three cases

1 reference

12 December 2020

Bezafibrate treatment: a new medical approach for PBC patients?

1 reference

12 December 2020

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

12 December 2020

Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver

1 reference

12 December 2020

Time course of histological progression in primary biliary cirrhosis

1 reference

12 December 2020

Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients

1 reference

12 December 2020

Follow-up of children with autoimmune hepatitis treated with cyclosporine

1 reference

12 December 2020

Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis

1 reference

12 December 2020

Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis

1 reference

12 December 2020

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

1 reference

12 December 2020

Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report

1 reference

12 December 2020

Controlled trial of prednisone and azathioprine in active chronic hepatitis

1 reference

12 December 2020

Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis

1 reference

12 December 2020

The evidence supports a viral aetiology for primary biliary cirrhosis

1 reference

12 December 2020

Identifiers

DOI

10.1177/2040622313478646

1 reference

1 August 2017

1 reference

1 August 2017

1 reference